Anixa Biosciences, Inc. (ANIX)
2.68
-0.10
(-3.60%)
USD |
NASDAQ |
Nov 12, 16:00
2.72
+0.04
(+1.49%)
After-Hours: 20:00
Anixa Biosciences Enterprise Value : 77.73M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 77.73M |
| November 11, 2026 | 81.18M |
| November 10, 2026 | 90.87M |
| November 09, 2026 | 94.33M |
| November 06, 2026 | 94.85M |
| November 05, 2026 | 89.83M |
| November 04, 2026 | 98.48M |
| November 03, 2026 | 90.70M |
| November 02, 2026 | 88.45M |
| October 30, 2026 | 92.94M |
| October 29, 2026 | 99.17M |
| October 28, 2026 | 101.59M |
| October 27, 2026 | 98.48M |
| October 26, 2026 | 86.37M |
| October 23, 2026 | 88.45M |
| October 22, 2026 | 81.18M |
| October 21, 2026 | 78.76M |
| October 20, 2026 | 77.73M |
| October 19, 2026 | 75.31M |
| October 16, 2026 | 77.38M |
| October 15, 2026 | 81.18M |
| October 14, 2026 | 76.86M |
| October 13, 2026 | 77.38M |
| October 12, 2026 | 83.26M |
| October 09, 2026 | 85.34M |
| Date | Value |
|---|---|
| October 08, 2026 | 85.68M |
| October 07, 2026 | 87.06M |
| October 06, 2026 | 89.49M |
| October 05, 2026 | 87.06M |
| October 02, 2026 | 87.06M |
| October 01, 2026 | 80.84M |
| September 30, 2026 | 86.37M |
| September 29, 2026 | 83.61M |
| September 28, 2026 | 81.53M |
| September 25, 2026 | 81.18M |
| September 24, 2026 | 81.18M |
| September 23, 2026 | 80.15M |
| September 22, 2026 | 81.53M |
| September 21, 2026 | 78.42M |
| September 18, 2026 | 80.84M |
| September 17, 2026 | 80.49M |
| September 16, 2026 | 74.96M |
| September 15, 2026 | 78.07M |
| September 14, 2026 | 81.88M |
| September 11, 2026 | 80.49M |
| September 10, 2026 | 80.15M |
| September 09, 2026 | 82.91M |
| September 08, 2026 | 85.34M |
| September 04, 2026 | 91.21M |
| September 03, 2026 | 90.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 6.429B |
| Oncolytics Biotech, Inc. | 42.70M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 1.891B |
| Vicapsys Life Sciences, Inc. | 16.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.625M |
| Total Expenses (Quarterly) | 2.606M |
| EPS Diluted (Quarterly) | -0.0762 |
| Earnings Yield | -11.56% |
| Normalized Earnings Yield | -11.56 |